$CLMT

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

Original reporting
Published Aug 10, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Calumet Stock Is Rocketing Higher Today — source image
Decision brief

The 30-second read

$CLMTBullishMed
01

Why it matters

Bank of America’s higher price target is presented as the key driver, supported by reported Q2 free cash flow and recent debt retirement, implying improved credit and equity risk perception.

02

Market read

This is a single-name catalyst story: an analyst PT raise tied to balance-sheet strengthening is driving a large same-day move.

03

What to watch

The article does not provide updated production, margins, or policy/regulatory changes; traders may be over-weighting FCF and debt paydown without confirming forward cash-flow durability.

Relevance 7/10Novelty 6/10Timing: intraday, reported at 2:36 p.m. ET

Background

Calumet fell 6.8% last week before rebounding sharply on an analyst stance change.

Company-level read

Ticker impact

$CLMTBullishMedium confidence
Context

Calumet shares jump 15% as Bank of America lifts its price target to $45 from $38, citing stronger free cash flow and debt paydown.

Expected impact

Near-term upside bias likely persists while traders digest the PT increase and the debt-retirement narrative.

Evidence & confidence

The article attributes the move to a specific analyst action (PT raise) and ties it to concrete cash flow and debt reduction figures (Q2 FCF, $115M debt retired).

Market effects

Renewable fuels producers may see sentiment lift if balance-sheet deleveraging via free cash flow is rewarded by sell-side.

No specific regional spillover mentioned.

No direct global linkage beyond the renewable fuels theme.

Counterpoint

The move may fade if the market views the PT increase as incremental and not tied to new operational guidance or earnings results.

Key entities

  • Calumet

    Renewable fuels producer whose shares are up about 15% intraday on a Bank of America price-target increase.

  • Bank of America

    Raised Calumet’s price target to $45 from $38 while maintaining a buy rating, citing stronger free cash flow and debt retirement.

Related articles

$CLMTMedAI 8/10

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.

$CLMTMed

Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.